marijuana stocks news

DirectView Holdings, Inc. (DIRV)

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Total Revenue 97   159   112   143  
Cost of Revenue 120 110 180 53
Gross Profit (23) 48   (67) 90  
Operating Expenses
Research Development
Selling General and Administrative 212 245 360 613
Non Recurring 21
Others 2 2
Total Operating Expenses
Operating Income or Loss (257) (198) (427) (523)
Income from Continuing Operations
Total Other Income/Expenses Net 3,073 5,500 25,726 (34,028)
Earnings Before Interest And Taxes 13,811 (5,694) 25,299 (34,551)
Interest Expense 48 38 (1) 15
Income Before Tax 13,764 (5,731) 25,300 (34,566)
Income Tax Expense
Minority Interest 25 (37) 41 (19)
Net Income From Continuing Ops 13,789 (5,769) 36,337 (34,586)
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income 2,793   5,227   25,341   (34,586)
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares 2,793   5,227   25,341   (34,586)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$CBIS Partners With FHP.TV & Kush Boys Studios

Cannabis Science Partners With FHP.TV & Kush Boys Studios to Host Its…

 Green Thumb Industries Inc. (GTBIF) Closes on Acquisition of Massachusetts Cannabis Operator Liberty Compassion Inc.

Green Thumb Closes on Acquisition of Massachusetts Cannabis Operator Liberty Compassion Inc.…

$ZDPY Eliminates Current Debt, Retires $1 Million of Convertible Notes

Zoned Properties Eliminates Current Debt, Retires $1 Million of Convertible Notes  Zoned…

GT BIOPHARMA, INC. ANNOUNCES ADDITIONAL POSITIVE DATA FROM ITS PHASE 1 CLINICAL TRIAL FOR MYASTHENIA GRAVIS AND POTENTIAL FOR ACCELERATION OF THE START OF ITS PHASE 2 TRIAL

WASHINGTON, DC / MARCH 26, 2018 / GT Biopharma Inc. (OTCQB “GTBP”…